Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations.
暂无分享,去创建一个
Tara Kirk Sell | Eric Toner | Matthew Watson | Kunal J Rambhia | E. Toner | Kunal J. Rambhia | Matthew Watson | T. Sell | R. Waldhorn | Richard Waldhorn | Eric S Toner
[1] L. Balluz,et al. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[2] R. Blendon,et al. The public's response to the 2009 H1N1 influenza pandemic. , 2010, The New England journal of medicine.
[3] G. Gronvall,et al. Influenza vaccine production for the U.S. market. , 2009, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[4] L. Balluz,et al. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage --- United States, October-December 2009. , 2010, MMWR. Morbidity and mortality weekly report.
[5] Atlanta,et al. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel - United States, August 2009-January 2010. , 2010, MMWR. Morbidity and mortality weekly report.
[6] H. Pereira,et al. Swine influenza , 1976, Nature.
[7] D. Henderson. Universal influenza vaccination: an optimal goal--but how and when? , 2010, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[8] M. Hogue,et al. Pharmacist involvement with immunizations: a decade of professional advancement. , 2006, Journal of the American Pharmacists Association : JAPhA.
[9] S. Blank,et al. An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001. , 2003, Emerging infectious diseases.